Otonomy
Autonomous defense systems including drones, actuators, and autonomy software
- Sector
- Biotech
- Headquarters
- SAN DIEGO, CA
- Founded
- 2008
- Latest Form D
- $10M, Sep 2010
- Total capital
- $20.6M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $20.6M
- 2 Form D · last Sep 2010
- 194 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 23 pending · first 2021
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$10M
- Private capital raisedForm D · SEC · 1st filing$10.6M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Carl LeBelResearcherExecutive OfficerLinked by 1 patent
- Brian DoveyDirectorNamed in SEC Form D filings
- Carl LeBel, Ph.D.Executive OfficerNamed in SEC Form D filings
- Court TurnerExecutive OfficerNamed in SEC Form D filings
- David WeberExecutive Officer, DirectorNamed in SEC Form D filings
- Douglas DownsExecutive OfficerNamed in SEC Form D filings
Show all 15 people
- Gerald WroblewskiExecutive OfficerNamed in SEC Form D filings
- Heather PrestonDirectorNamed in SEC Form D filings
- Jay LichterDirectorNamed in SEC Form D filings
- Jay Lichter, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
- Jeffrey HarrisDirectorNamed in SEC Form D filings
- Jeffrey Harris, M.D., Ph.D.DirectorNamed in SEC Form D filings
- John McKearnDirectorNamed in SEC Form D filings
- Paul CayerExecutive OfficerNamed in SEC Form D filings
- Peter BisgaardDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 24- GrantedOtic Gel Formulations For Treating Otitis ExternaUSPTOUS 11,040,004
- PendingTriglyceride Otic Formulations And Uses ThereofUSPTOApplication 17011910
- PendingTrkb Or Trkc Agonist Compositions And Methods For The Treatment Of Otic ConditionsUSPTOApplication 16726145
Show all 24 patent records
- Otic Gel Formulations For Treating Otitis ExternaJun 22, 2021 · US 11,040,004Granted
- Triglyceride Otic Formulations And Uses ThereofDec 24, 2020 · Application 17011910Pending
- Trkb Or Trkc Agonist Compositions And Methods For The Treatment Of Otic ConditionsJun 18, 2020 · Application 16726145Pending
- Neurotrophin Mutants For Treating Hearing Loss And Other Otic DisordersDec 12, 2019 · Application 16481245Pending
- Prevention Of And Recovery From Drug-induced OtotoxicityFeb 8, 2018 · Application 15788610Pending
- Variant Adeno-associated Virus (aav) Capsid Polypeptides For Treatment Of Hearing LossApplication 63110697Pending
- Otic Formulations For Drug-induced OtotoxicityApplication PCTUS2020058423Pending
- Gacyclidine Otic Formulations And Uses ThereofApplication 63129358Pending
- Growth Factor Formulation For Condition Associated With Otic EventApplication 62965758Pending
- Growth Factor Formulation For Condition Associated With Otic EventApplication PCTUS2021014781Pending
- GSK-3 Modulator Otic FormulationsApplication 62949379Pending
- Otic Formulations For Drug-induced OtotoxicityApplication 62928196Pending
- Gacyclidine Otic Formulations And Uses ThereofApplication PCTUS2021065006Pending
- Otic Formulations For Drug-induced OtotoxicityApplication PCTUS2019029231Pending
- Otic Formulations For Drug-induced OtotoxicityApplication 62803149Pending
- Growth Factor Otic FormulationsApplication PCTUS2019012941Pending
- Triglyceride Otic Formulations And Uses ThereofApplication PCTUS2018067344Pending
- Otic Formulations For Drug-induced OtotoxicityApplication 62662653Pending
- Neurotrophin Mutants For Treating Hearing Loss And Other Otic DisordersApplication PCTUS2018015548Pending
- Growth Factor Otic FormulationsApplication 62615358Pending
- Triglyceride Otic Formulations And Uses ThereofApplication 62609491Pending
- Otic Gel Formulations For Treating Otitis MediaApplication PCTUS2017053715Pending
- Otic Growth Factor Compositions And Therapeutic UsesApplication 63125902Pending
- Variant Adeno-associated Virus (aav) Capsid Polypeptides For Treatment Of Hearing LossApplication 63146269Pending
Related companies, and why
- LumaCyte, Inc.Similar federal contract value in Biotech · null in contracts
- Surface Ophthalmics, Inc.Similar federal contract value in Biotech · null in contracts
- MethylGene Inc.Similar federal contract value in Biotech · null in contracts
- Endlyz Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Avilar TherapeuticsSimilar federal contract value in Biotech · null in contracts
- SUPERNUS PHARMACEUTICALS INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .